BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, July 5, 2026
Breaking News: Science fiction realized: BCI tech is hereBreaking News: Science fiction realized: BCI tech is hereBreaking News: Science fiction realized: BCI tech is here
Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
BioWorld Science, Cancer RSS Feed RSS

Colorectal cancer illustration
Cancer

DUSP18 blockade induces antitumor immune activity in colorectal cancer

July 18, 2024
Tumor cells use metabolic reprogramming for their survival and to fuel and boost their proliferation. Only 15% of patients with colorectal cancer (CRC) benefit from immune checkpoint blockade therapy, mainly due to tumor microenvironment changes to promote CD8+ T-cell exhaustion and inactivation allowing tumor cells to escape from immunity.
Read More
Cancer

Inhibiting epigenetic regulator blocks liver cancer development

July 18, 2024
Transposable elements (TEs) are DNA sequences involved in the epigenetic regulation of tumors. KDM1A is an epigenetic regulator overexpressed in liver cancer that suppresses the methylation of histone H3 Lys4 (H3K4) in liver-TEs and as a result, HNF4A expression is silenced and hepatocellular carcinoma (HCC) growth is promoted.
Read More
3D representation of tumor
Cancer

Inhibition of mutant IDH1 restores solid tumor immune sensitivity

July 18, 2024
By Xavier Bofill Bruna
Mutations in the metabolic enzyme isocitrate dehydrogenase 1 (IDH1) induce tumorigenesis due to generation of the oncometabolite (R)-2-hydroxyglutarate (R-2HG). A hallmark of solid tumors carrying mutations in IDH1 is immune evasion by T-cell exclusion and altered epigenetic state. Researchers from the Center for Cancer Research, Massachusetts General Hospital have published a study in Science on July 12, 2024, in which they demonstrate that inhibiting mutant IDH1 restored antitumoral immunity.
Read More
Cancer

University of Regensburg discovers new FLT3 inhibitors for AML

July 17, 2024
University of Regensburg has described water-soluble FLT3 (FLK2/STK1) inhibitors and their prodrugs reported to be useful for the treatment of acute myeloid leukemia (AML).
Read More
Cancer

Shenzhen Bay Laboratory describes new USP1 inhibitors

July 17, 2024
Shenzhen Bay Laboratory has identified ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.
Read More
Cancer

Hangzhou Zhongmei Huadong Pharmaceutical divulges new GTPase KRAS degradation inducers

July 17, 2024
Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd. has synthesized proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently bonded to a GTPase KRAS (G12D mutant) targeting moiety through a linker reported to be useful for the treatment of cancer.
Read More
Cancer

Insilico Medicine patents new CBL-B inhibitors

July 17, 2024
Insilico Medicine Inc. has disclosed E3 ubiquitin-protein ligase CBL-B (CBLB) inhibitors reported to be useful for the treatment of cancer.
Read More
Purple-tinted test tubes and dropper
Cancer

Novel selective BD1 inhibitor divulged

July 17, 2024
The bromodomain and extraterminal (BET) subfamily contain two similar tandem bromodomains (BD1 and BD2). Selective inhibition of BD2 has been deeply explored; however, the obtention of selective and potent BD1 inhibitors is essential and still lacking.
Read More
Clinical research concept with medical icons on light bulb
Cancer

Grant supports Children’s Cancer Institute to develop treatment for diffuse intrinsic pontine glioma

July 17, 2024
A researcher at Australia’s Children’s Cancer Institute has been awarded a 3-year US$400,000 grant by the Chadtough Defeat DIPG Foundation to develop and test a new drug candidate for diffuse intrinsic pontine glioma (DIPG).
Read More
Multiple myeloma cells in the bone marrow.
Cancer

Targeting LILRB1 disrupts cholesterol homeostasis and promotes MM cell ferroptosis

July 17, 2024
Previous studies have suggested the importance of cholesterol metabolism in multiple myeloma (MM) cells. Since ferroptosis is closely related to lipid metabolism, researchers from Houston Methodist Research Institute aimed to investigate the crosstalk between metabolic reprogramming and ferroptosis in MM cells.
Read More
Previous 1 2 … 302 303 304 305 306 307 308 309 310 … 3712 3713 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 2, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 30, 2026
  • Black wavy lines forming an abstract sound wave.png

    Deep brain stimulation from the shallows: tomorrow’s BCI technology?

    BioWorld
    Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...
  • AI-generated image for brain organoid neural research

    CINP 2026: organoids reveal autism and addiction mechanisms

    BioWorld Science
    At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
  • Handshake, businessmen holding dollar sign, lightbulb

    Deerfield-backed Boulevard, Metis pen $1.6B trispecific TCE deal

    BioWorld
    A U.S. biotechnology company founded by Deerfield Management Company L.P. licensed exclusive rights to Metis Techbio Co. Ltd.’s preclinical trispecific T-cell...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing